AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Principal_NN
Subsidiaries_NN
112_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Principal_NN
Subsidiaries_NN
Percentage_NN
of_PIN
voting_VBG [SUAV]
At_PIN
31_CD
December_NN
2003_CD
Country_NN
share_NN
capital_NN
held_VBD [PRIV]
Principal_NN
activity_NOMZ
UK_NN
AstraZeneca_NN
UK_NN
Limited_NN
England_NN
100_CD
#_#
Research_NN
and_PHC
development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
Insurance_NN
Company_NN
Limited_NN
England_NN
100_CD
Insurance_NN
and_PHC
reinsurance_NN
underwriting_GER
AstraZeneca_NN
Treasury_NN
Limited_NN
England_NN
100_CD
Treasury_NN
Continental_NN
Europe_NN
NV_NN
AstraZeneca_NN
SA_NN
Belgium_NN
100_CD
Marketing_GER
AstraZeneca_NN
Dunkerque_NN
Production_NOMZ
SCS_NN
France_NN
100_CD
Production_NOMZ
AstraZeneca_NN
SA_NN
France_NN
100_CD
Research_NN
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
GmbH_NN
Germany_NN
100_CD
Development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
Holding_GER
GmbH_NN
Germany_NN
100_CD
Production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
SpA_NN
Italy_NN
100_CD
Production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
Farmaceutica_NN
Spain_NN
SA_NN
Spain_NN
100_CD
Production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
AB_NN
Sweden_NN
100_CD
Research_NN
and_PHC
development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
BV_NN
The_NN
Netherlands_NN
100_CD
Marketing_GER
The_DT
Americas_NN
AstraZeneca_NN
Canada_NN
Inc._NN
._.
Canada_NN
100_CD
Research_NN
,_,
production_NOMZ
,_,
marketing_GER
IPR_NN
Pharmaceuticals_NN
Inc._NN
._.
Puerto_NN
Rico_NN
100_CD
Development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
LP_NN
US_FPP1
99_CD
Research_NN
and_PHC
development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
US_FPP1
100_CD
Research_NN
and_PHC
development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
Zeneca_NN
Holdings_GER
Inc._NN
._.
US_FPP1
100_CD
Production_NOMZ
,_,
marketing_GER
Asia_NN
,_,
Africa_NN
&_CC
Australasia_NN
AstraZeneca_NN
Pty_NN
Limited_NN
Australia_NN
100_CD
Development_NOMZ
,_,
production_NOMZ
,_,
marketing_GER
AstraZeneca_NN
KK_NN
Japan_NN
80_CD
Production_NOMZ
,_,
marketing_GER
#_#
Shares_NN
held_VBD [PRIV]
directly_RB
The_DT
companies_NN
and_CC
other_JJ
entities_NOMZ
listed_VBN [WZPAST]
above_PLACE
are_VPRT [BEMA]
those_DEMP
whose_WPS
results_NN
or_CC
financial_JJ
position_NOMZ
principally_RB
affected_VBD
the_DT
figures_NN
shown_VBN [PRIV] [WZPAST]
in_PIN
the_DT
Groups_NN
annual_JJ
Financial_NN
Statements_NOMZ
._.
A_DT
full_JJ
list_NN
of_PIN
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
will_PRMD
be_VB [PASS]
annexed_VBN
to_PIN
the_DT
Companys_NN
next_JJ
annual_JJ
return_NN
filed_VBN [WZPAST]
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
The_DT
country_NN
of_PIN
registration_NOMZ
or_CC
incorporation_NOMZ
is_VPRT [PASS]
stated_VBN [PUBV]
alongside_PLACE
each_QUAN
company_NN
._.
The_DT
accounting_GER
dates_NN
of_PIN
subsidiaries_NN
and_PHC
associates_NN
are_VPRT [BEMA]
31_CD
December_NN
,_,
except_PIN
for_PIN
Salick_NN
Health_NN
Care_NN
,_,
Inc._NN
which_WDT [WHOBJ]
,_,
owing_VBG [PRESP]
to_PIN
local_JJ
conditions_NOMZ
and_CC
to_TO
avoid_VB
undue_JJ
delay_NN
in_PIN
the_DT
preparation_NOMZ
of_PIN
the_DT
Financial_NN
Statements_NOMZ
,_,
is_VPRT [BEMA]
30_CD
November_NN
._.
AstraZeneca_NN
operates_VPRT
through_PIN
234_CD
subsidiaries_NN
worldwide_JJ
._.
The_DT
Group_NN
Financial_NN
Statements_NOMZ
consolidate_VB
the_DT
Financial_NN
Statements_NOMZ
of_PIN
AstraZeneca_NN
PLC_NN
and_CC
its_PIT
subsidiaries_NN
at_PIN
31_CD
December_NN
2003_CD
._.
Products_NN
are_VPRT [PASS]
manufactured_VBN
in_PIN
some_QUAN
20_CD
countries_NN
worldwide_JJ
and_CC
are_VPRT [PASS]
sold_VBN
in_PIN
over_IN
100_CD
countries_NN
._.
